This is an aggregated industry headline. Read the full story at Endpoints News →
CSL sinks to nine-year low on revenue warning, $5B write-down
CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by about 4% and said it would have to take a new $5 billion impairment charge. The ...
By Endpoints News
· May 11, 2026
· via Endpoints News
Image: Endpoints News
Tags
moneyformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
MoneyFierceBiotech ↗
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million…
MoneyFiercePharma ↗
Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to…
MoneyBriefing
Vancouver’s Optimi Health launched a 2.5M-share IPO just as U.S. policy momentum boosts psychedelics research,…